Peroxisome proliferator-activated receptor 3D structures

3D Structures of PPAR3D Structures of PPAR

Updated on 23-August-2023 {{#tree:id=OrganizedByTopic|openlevels=0|

• PPARα;Ligand-binding domain 201-468

• • 1k7l – hPPARα + G2409544 + NCOA1 - human
    
  • 3e94 – hPPARα + fatty acid activator
    
  • 4bcr, 5hyk - hPPARα + ligand
    
  • 1kkq – hPPARα + GW6471 Antagonist + SMRT
    
  • 2p54 - hPPARα + NCOA1
    
  • 5azt - hPPARα (mutant) + NCOA1 peptide
    
  • 2rew - hPPARα + azetidinone derivative activator
    
  • 2znn, 2zno, 2znp, 2znq, 3kdu, 3vi8, 1i7g, 4bcr, 5hyk - hPPARα + agonist
    
  • 3fei, 3fej, 3g8i, 3sp6, 6l96 - hPPARα + agonist + NCOA1 peptide
    
  • 3sp6 - hPPARα + hPPARγ peptide + agonist
    
  • 6kxx, 6kxy - hPPARα + peptide + agonist
    
  • 7c6q - hPPARα + peptide + sanguinarine
    
  • 3et1 - hPPARα + NCOA1 + indole derivative
    
  • 6kb7, 6kba - hPPARα + pyrimidine derivative
    
  • 7e5f, 7e5g, 7e5h, 7e5i - hPPARα + propanoic acid derivative
    
  • 2npa - hPPARα + propanoic acid derivative + NCOA1
  • 6jey, 6kax, 6kay, 6kaz ,6kb0, 6kb1, 6kb2, 6kb3, 6kb4 ,6kb5, 6kb6 ,6kb8, 6kb9, 6lx4, 6lx5, 6lx6, 6lx7, 6lx8, 6lx9, 6lxa, 6lxb, 6lxc - hPPARα + ampiphatic carboxylic acid derivative
    
  • 7bpy, 7bpz, 7bq0, 7bq1, 7bq2, 7bq3, 7bq4 - hPPARα + NCOA1 + ampiphatic carboxylic acid derivative
    
  • 6l38 - hPPARα + benzamide derivative
    
  • 8hun, 8huo - hPPARα + anti-NASH drug
    
  • 6kyp, 6l36, 6l37 - hPPARα + benzamide derivative + propanoic acid derivative
    
  • 8huq, 8huk, 8hum - hPPARα + NCOA1 peptide + anti-NASH drug
    

• • 5azt - hPPARα (mutant) + NCOA1 peptide
    

• PPARγ;Ligand-binding domain 202-475

• • 3prg, 2qmv, 1prg, 6l8b, 6vzo, 8cpj – hPPARγ
    
  • 6fzy, 6fzg, 6t1s, 6vzn, 7cxe, 7e2o - hPPARγ (mutant)
    
  • 2zk0, 2zk1, 2zk2, 2zk3, 2zk4, 2zk5, 2zk6, 3vjh, 3vji, 4e4k, 4e4q, 4jl4, 5hzc, 4ci5, 4ci4, 6an1, 2f4b, 1zeo, 2ath, 2hwq, 2hwr, 2i4j, 2q59, 2q8s, 3b3k, 3bc5, 3cds, 3g9e, 3gbk, 3gz9, 3ia6, 3kdt, 3an3, 3an4, 3noa, 3r5n, 3r8a, 3vso, 3vsp, 2xkw, 3b0q, 3ho0, 3hod, 1knu, 1i7i, 1nyx, 2pob, 5azv, 6f2l, 6c5t, 6c5q, 5wr1, 5wr0, 5wqx, 6md2, 6md4, 6md1, 6md0, 6mcz, 6k0t, 6avi, 6aug, 6qj5, 6t9c, 6tdc, 6vzl, 7lot, 7jqg, 7wox – hPPARγ + ligand
    
  • 4l98, 4l96 - hPPARγ (mutant) + ligand
    
  • 3r8i - hPPARγ + ureidofibrate derivative
    
  • 6o67, 6o68, 6dgr, 6dgq, 6dgo, 6dgl, 6d8x, 6c1i - hPPARγ + agonist
    
  • 2g0h, 2g0g, 2i4p, 2i4z, 2q5g, 2q5p, 2q5s, 2q61, 2q6r, 3cdp, 3d6d, 4em9, 4ema, 4prg, 2q6s, 5f9b, 4yt1, 3wmh, 6d3e, 6l89, 7p4e, 8dsz - hPPARγ + partial agonist
    
  • [[7sqb, 8dsy hPPARγ + inverse agonist
    
  • 2om9 - hPPARγ + cannabinoid
    
  • 3b0r, 5lsg, 4r6s, 4r2u, 4r06, 6dh9, 6dcu, 6dbh - hPPARγ + antagonist
    
  • 3osi, 3osw, 3pba - hPPARγ + bisphenol derivative
    
  • 2p4y, 3adt, 3adu, 3adw, 3et3, 2hfp, 3ty0, 5two, 6fzj, 6t6b, 6y3u, 7a7h, 8aty, 8atz, 8cph, 8cpi - hPPARγ + modulator
    
  • 2zvt - hPPARγ (mutant) + modulator
    
  • 2vsr, 2vst, 2vv0, 2vv1, 2vv2, 2vv3, 2vv4, 3x1i, 3x1h, 3wj5, 3wj4, 3po9, 3sz1, 8bf2, 8bff - hPPARγ + fatty acid activator
    
  • 6jey - hPPARγ + fatty acid
    
  • 6jf0, 7efq - hPPARγ + fluorescent probe
    
  • 6mcz, 6md0, 6md1, 6md2, 6qj5, 6t9c - hPPARγ + ligand
    
  • 6tsg - hPPARγ + hormone
    
  • 3ads, 3adx, 5u5l, 4xum, 4xuh, 4xta, 4xld, 6d5a, 6o67, 6o68, 7ahj, 7awc, 7awd, 7e0a - hPPARγ + anti-inflammatory drug
    
  • 4oj4 - hPPARγ (mutant) + anti-inflammatory drug
    
  • 3adv - hPPARγ + serotonin
    
  • 3k8s, 3et0, 2yfe, 4a4v, 4a4w, 4jaz, 5tto, 4pwl, 4pvu, 5y2t, 5y2o, 5ugm, 6dha - hPPARγ + antidiabetic drug
    
  • 4o8f, 6vzm - hPPARγ (mutant) + antidiabetic drug
    
  • 6md4 - hPPARγ + oleic acid + antidiabetic drug
    
  • 6enq - hPPARγ + antifibrotic drug
    
  • 6zly - hPPARγ + valine derivative
    

• • 7qb1, 8adf, 8c0c, 8dkv - hPPARγ + inhibitor
    
  • 8hup - hPPARg + NCOA1 peptide + anti-NASH drug
    

• PPARγ complex with NCAO1

• • 2gtk, 3qt0, 5gtp, 5gto, 5gtn, 5ycp, 5ycn, 5z6s, 5z5s, 6dgp, 6ilq, 6ijs, 6ijr, 6icj, 6jq7, 6ktm, 7cxf - hPPARγ + NCOA1 peptide
    
  • 6t1v, 7cxg, 7cxh, 7cxi, 7cxj, 7cxk, 7cxl - hPPARγ (mutant) + NCOA1 peptide
    
  • 6ktn - hPPARγ (mutant) + NCOA1 peptide + leukemia drug
    
  • 3fur, 3kmg, 3v9t, 3v9v, 3v9y, 4f9m, 3b1m, 3lmp, 6fzp, 8dk4 - hPPARγ + NCOA1+ modulator
    
  • 6fzf - hPPARγ (mutant) + NCOA1+ modulator
    
  • 4fgy, 2prg - hPPARγ + antidiabetic drug + NCOA1 peptide
    
  • 7wgo, 7wgq - hPPARγ + hyperlipidaemia drug + NCOA1 peptide
    
  • 7wgp - hPPARγ + pancreatitis drug + NCOA1 peptide
    
  • 6ad9 - hPPARγ + anticancer agent + NCOA1 peptide
    
  • 6izm, 6izn, 8dkn - hPPARγ + pyridine derivative + NCOA1 peptide
    
  • 3s9s, 3t03, 2fvj- hPPARγ + NCOA1 peptide + partial agonist
    
  • 4y29, 2fvj, 5azt - hPPARγ + NCOA1 peptide + ligand
    
  • 3h0a - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + partial agonist
    
  • 1k74, 1rdt, 1fm9 - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + agonist
    
  • 5ji0 - hPPARγ + retinoic acid receptor + NCOA1 peptide + antidiabetic drug
    
  • 3vn2, 4hee, 4prg - hPPARγ + NCOA1 peptide + activator
    

• PPARγ complex with NCAO2

• • 1wm0 – hPPARγ + NCAO2 peptide + agonist
    
  • 5dwl, 5dvc, 5dv8, 5dv6, 5dv3, 5dsh - hPPARγ + NCAO2 peptide + inhibitor
    
  • 7sqa, 8aqm, 8aqn, 8b8w, 8b8x, 8b8y, 8b90, 8b92, 8b93, 8b94, 8b95- hPPARγ + NCOA2 peptide + inverse agonist
    
  • 8b8z, 8b91 - hPPARγ (mutant) + NCOA2 peptide + inverse agonist
    
  • 3dzu, 3e00, 3dzy - hPPARγ + DNA + retinoic acid receptor + NCOA2 peptide + retinoic acid
    
  • 1fm6 - hPPARγ + antidiabetic drug + retinoic acid receptor + NCOA2 peptide + retinoic acid
    

• PPARγ complex with other proteins

• • 1zgy – hPPARγ + antidiabetic drug + nuclear receptor peptide
    
  • 3cs8, 3u9q, 8bf1 - hPPARγ + PGC-1A peptide
    
  • 3cwd - hPPARγ + SRC1-2
    
  • 6oni, 6pdz - hPPARγ +inverse agonist + NCOR peptide
    
  • 6ms7 - hPPARγ + PGC1 LXXLL + modulator
    
  • 6d94 - hPPARγ + mediator of RNA polymerase II peptide
    
  • 6onj - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug
    
  • 7rle - hPPARγ + CREB-binding protein peptide + agonist
    

• PPARδ;Ligand-binding domain 171-441

• • 2gwx – hPPARδ
    
  • 2env – hPPARδ zinc finger domain 72-146 - NMR
    
  • 2baw, 2b50, 2awh – hPPARδ + Vaccenic Acid
    
  • 3gwx – hPPARδ + 5,8,11,14,17-Eicosapentaenoic Acid
    
  • 3dy6 – hPPARδ + anthranilic acid
    
  • 3et2, 1gwx – hPPARδ + fatty acid
    
  • 2j14, 2xyj, 2xyw, 2xyx, 3oz0, 3sp9, 5u3q, 5u3r, 5u3s, 5u3t, 5u3u, 5u3v, 5u3w, 5u3x, 5u3y, 5u3z, 5u40, 5u41, 5u42, 5u43, 5u44, 5u45, 1gwx, 3tkm, 1y0s, 5u46, 5y7x, 7vwf, 7vwg, 7vwh, 7w0g, 7wgn, 8hul - hPPARδ + agonist
    
  • 3peq - hPPARδ + partial agonist
    
  • 3d5f - hPPARδ + phenoxy derivative
    
  • 5xmx, 6a6p, 5zxi, 7f80 - hPPARδ + inhibitor
    
  • 7wgl - hPPARd + hyperlipidaemia drug
    

}}